CN107949563B - 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 - Google Patents

治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 Download PDF

Info

Publication number
CN107949563B
CN107949563B CN201680036895.1A CN201680036895A CN107949563B CN 107949563 B CN107949563 B CN 107949563B CN 201680036895 A CN201680036895 A CN 201680036895A CN 107949563 B CN107949563 B CN 107949563B
Authority
CN
China
Prior art keywords
pyrazolo
dimethoxyphenyl
dimethyl
methyl
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680036895.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107949563A (zh
Inventor
J.维斯特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curovir AB
Original Assignee
Curovir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curovir AB filed Critical Curovir AB
Publication of CN107949563A publication Critical patent/CN107949563A/zh
Application granted granted Critical
Publication of CN107949563B publication Critical patent/CN107949563B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680036895.1A 2015-06-24 2016-06-10 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 Active CN107949563B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173687.3 2015-06-24
EP15173687 2015-06-24
PCT/EP2016/063383 WO2016206999A1 (en) 2015-06-24 2016-06-10 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy

Publications (2)

Publication Number Publication Date
CN107949563A CN107949563A (zh) 2018-04-20
CN107949563B true CN107949563B (zh) 2020-06-05

Family

ID=53483747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680036895.1A Active CN107949563B (zh) 2015-06-24 2016-06-10 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物

Country Status (10)

Country Link
US (1) US10407429B2 (https=)
EP (1) EP3313842B1 (https=)
JP (1) JP6689299B2 (https=)
CN (1) CN107949563B (https=)
AU (1) AU2016284638B2 (https=)
BR (1) BR112017026061B1 (https=)
CA (1) CA2989722C (https=)
RU (1) RU2712196C2 (https=)
WO (1) WO2016206999A1 (https=)
ZA (1) ZA201800485B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
DK3606926T3 (da) 2017-04-05 2021-07-05 Curovir Ab Heteroaromatiske forbindelser anvendelige i terapi
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
SG11202012616RA (en) 2018-08-21 2021-02-25 Kyorin Pharmaceutical Co Ltd Bicyclic heteroaromatic ring derivative
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
CA3115128A1 (en) * 2018-10-10 2020-04-16 Curovir Ab 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
CA3126143A1 (en) * 2019-01-11 2020-07-16 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
KR20220035322A (ko) 2019-03-21 2022-03-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Pi4-키나아제 억제제 및 이의 사용 방법
EP4028131B1 (en) 2019-08-20 2023-11-22 Curovir Ab Heteroaromatic compounds useful in therapy
CN113801119B (zh) * 2021-08-30 2022-09-30 新乡医学院 一种吡唑并[1,3,5]三嗪类化合物的合成方法
EP4676485A1 (en) 2023-03-09 2026-01-14 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
WO2001023387A2 (en) * 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049699B1 (en) * 1998-01-28 2004-04-21 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
US9573954B2 (en) * 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO2001023387A2 (en) * 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Highly Selective Phosphatidylinositol 4‑Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action;Ivana Mejdrova等;《J. Med. Chem.》;20150421;第58卷;第3767−3793页 *

Also Published As

Publication number Publication date
AU2016284638B2 (en) 2020-01-23
RU2712196C2 (ru) 2020-01-24
EP3313842B1 (en) 2020-04-15
CA2989722A1 (en) 2016-12-29
US10407429B2 (en) 2019-09-10
ZA201800485B (en) 2020-05-27
WO2016206999A1 (en) 2016-12-29
JP2018522861A (ja) 2018-08-16
AU2016284638A1 (en) 2018-01-18
NZ738280A (en) 2024-10-25
EP3313842A1 (en) 2018-05-02
CA2989722C (en) 2023-09-19
CN107949563A (zh) 2018-04-20
US20180298007A1 (en) 2018-10-18
JP6689299B2 (ja) 2020-04-28
BR112017026061B1 (pt) 2023-03-28
BR112017026061A2 (pt) 2018-08-14
RU2018102449A3 (https=) 2019-08-20
RU2018102449A (ru) 2019-07-24
HK1254809A1 (en) 2019-07-26

Similar Documents

Publication Publication Date Title
CN107949563B (zh) 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
RU2770363C2 (ru) Гетероароматические соединения, пригодные в терапии
CN106061975B (zh) 作为抗病毒化合物的吡唑并[1,5-a]嘧啶
CN112969703B (zh) 用于治疗病毒感染的化合物
HK1254809B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
HK40019049A (en) Heteroaromatic compounds useful in therapy
HK40019049B (en) Heteroaromatic compounds useful in therapy
BR112019019796B1 (pt) Composto, composição farmacêutica, e, uso de composto ou de sal farmaceuticamente aceitável

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant